Benmassaoud A, et al. - In this study, the short-term and long-term efficacy and safety of infliximab (IFX) and adalimumab (ADA) were compared in the case of Crohn's disease (CD). Findings revealed that patients started on IFX were more likely to have a harder-to-treat phenotype. Despite that, between both groups, efficacy endpoints were similar. In patients with combination therapy for IFX, clinical remission was higher, but not for those on ADA.